Semnur Pharmaceuticals, Inc. financial data

Symbol
SMNR, SMNRW on OTC
Location
Palo Alto, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 27 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.9% % -94%
Debt-to-equity -48% % -3.2%
Return On Equity 521% % 5166%
Return On Assets -5424% % -39460%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 230,209,142 shares
Common Stock, Shares, Outstanding 230,209,142 shares 15%
Entity Public Float $500,000 USD -94%
Common Stock, Value, Issued $23,000 USD 15%
Weighted Average Number of Shares Outstanding, Basic 201,686,617 shares 0.84%
Weighted Average Number of Shares Outstanding, Diluted 201,686,617 shares 0.84%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $50,000,000 USD
Research and Development Expense $1,143,000 USD 391%
General and Administrative Expense $151,451,000 USD 14121%
Operating Income (Loss) $160,416,000 USD -3320%
Net Income (Loss) Attributable to Parent $160,416,000 USD -3831%
Earnings Per Share, Basic -0.76 USD/shares -7500%
Earnings Per Share, Diluted -0.76 USD/shares -7500%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $20,000 USD 67%
Other Assets, Current $0 USD -100%
Assets, Current $596,000 USD -90%
Property, Plant and Equipment, Net $750,000 USD 8.9%
Assets $1,346,000 USD -80%
Accounts Payable, Current $5,912,000 USD
Employee-related Liabilities, Current $469,000 USD
Accrued Liabilities, Current $739,000 USD 2011%
Liabilities, Current $10,168,000 USD 28951%
Liabilities $22,096,000 USD -55%
Retained Earnings (Accumulated Deficit) $275,800,000 USD -139%
Stockholders' Equity Attributable to Parent $20,750,000 USD 52%
Liabilities and Equity $1,346,000 USD -80%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $114,131 USD 69%
Net Cash Provided by (Used in) Financing Activities $100,000 USD -41%
Common Stock, Shares Authorized 740,000,000 shares 270%
Common Stock, Shares, Issued 230,209,142 shares 15%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $20,000 USD 67%
Deferred Tax Assets, Valuation Allowance $41,421,000 USD 139%
Deferred Tax Assets, Gross $41,421,000 USD 139%
Depreciation $0 USD
Property, Plant and Equipment, Gross $775,000 USD 8.5%
Deferred Tax Assets, Operating Loss Carryforwards $38,350,000 USD 164%
Preferred Stock, Shares Issued 5,423,606 shares
Preferred Stock, Shares Authorized 45,000,000 shares 0%
Unrecognized Tax Benefits $354,000 USD 0%
Preferred Stock, Shares Outstanding 5,423,606 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $140,192,000 USD 92132%
Interest Expense $28,345 USD 23%
Preferred Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%